Dublin, Jan. 28, 2022 (GLOBE NEWSWIRE) — The “Plasma Fractionation Market Forecast to 2028 – COVID-19 Impact and Global Analysis” report has been added to ResearchAndMarkets.com’s offering.
The plasma fractionation market is projected to reach US$ 40,731.98 million by 2028 from US$ 26,575.83 million in 2021; it is expected to grow at a CAGR of 6.3% during 2021-2028.
The market growth is mainly attributed to the rising application of plasma therapy and active participation of companies in market developments. However, the availability of recombinant or non-plasma counterparts. Further, development potential in emerging countries offers lucrative opportunities for the growth of the plasma fractionation market.
As stated in the previous driver, the market offers considerable potential for the companies operating the market-related businesses. Due to the positive market growth, the global and regional market players are actively adopting organic and inorganic development strategies. Thus it is expected to attract more significant investments in the market in the forecast period. For instance, below are some of the developments and initiatives adopted by the market players.
Based on application, the plasma fractionation market is segmented into neurology, immunology, hematology, critical care, pulmonology, and other applications. The neurology segment is expected to hold the largest share of the market in 2021 and is expected to register the highest CAGR during the forecast period….
